Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock [TheStreet.com]
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics (LUCD) had its price target raised by Ascendiant Capital Markets from $8.25 to $9.00. They now have a "buy" rating on the stock.
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]